Skip to main content
Catherine Wu, MD, Oncology, Boston, MA

Catherine Ju-Ying Wu MD

Hematologic Oncology


Assistant Professor of Medicine, Dana-Farber Cancer Institute

Join to View Full Profile
  • 450 Brookline Avenue, Dana 520CDana Farber Cancer InstituteBoston, MA 02215

  • Phone+1 617-632-5943

  • Fax+1 617-632-6380

Dr. Wu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1997 - 2000
  • Mass General Brigham/Brigham and Women's Hospital
    Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1994 - 1997
  • Stanford University School of Medicine
    Stanford University School of MedicineClass of 1994

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1996 - 2025

Awards, Honors, & Recognition

  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Cloning and Expression System to Probe T Cell Receptor Specificity and Assess Functional Avidity to Neoantigens  
    William J Lane, Patrick A Ott, Catherine J Wu, Donna E Leet, Blood

Abstracts/Posters

  • B Cell Restricted Expression of Mutated IKZF3 modulates BCR Signaling and Homing Pathways in a Mouse Model of CLL
    Catherine J. Wu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Deciphering the Role of Locally Disordered DNA Methylation on CLL Development In Vivo
    Catherine J. Wu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers
    Catherine J. Wu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Genome Editing for Transplantation and Cellular Therapies 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Clonal Dynamics in Chronic Lymphocytic Leukemia 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Response Comes of Age in Chronic Lymphocytic Leukemia 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Join now to see all

Press Mentions

  • Latent Viruses Inspire New Kidney Cancer Therapy
    Latent Viruses Inspire New Kidney Cancer TherapyMarch 1st, 2025
  • HMN 2025: How Genetic Evaluation Hyperlinks Immune Cell Profiles to Kidney Cancer Remedy Outcomes
    HMN 2025: How Genetic Evaluation Hyperlinks Immune Cell Profiles to Kidney Cancer Remedy OutcomesMarch 1st, 2025
  • Cancer Vaccine Promising for Late-Stage Kidney Cancer
    Cancer Vaccine Promising for Late-Stage Kidney CancerFebruary 6th, 2025
  • Join now to see all

Grant Support

  • Spatial genomic tools to interrogate T cell clonotypes, tumor clones and the microenvironmentBROAD INSTITUTE, INC.2023–2028
  • Spatial genomic tools to interrogate T cell clonotypes, tumor clones and the microenvironmentBROAD INSTITUTE, INC.2023–2028
  • Cancer Immune Monitoring and Analysis CenterDANA-FARBER CANCER INST2017–2028
  • Personal tumor neoantigens for immunity against chronic lymphocytic leukemiaDANA-FARBER CANCER INST2011–2027
  • Systematic identification of minor histocompatibility antigens to address GVHDDANA-FARBER CANCER INST2022–2026
  • Comprehensive dissection of the CLL genome & phenome to improve patient outcomesDANA-FARBER CANCER INST2016–2026
  • Post-Transplant Vaccines To Enhance Graft-Versus-Leukemia ResponsesNational Heart, Lung, And Blood Institute2010–2011
  • GM-CSF Secreting Tumor Cell Vaccines To Enhance Post-Transplant Anti-Cll ImmunityNational Cancer Institute2008–2009
  • GM - CSF - Producing Tumor Cell LINE As A CML VaccineNational Cancer Institute2006
  • GM-CSF - Producing Tumor Cell LINE As A CML VaccineNational Cancer Institute2005
  • Leukemia Antigens Following Donor Leukocyte InfusionNational Heart, Lung, And Blood Institute2000–2004

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: